Overview

A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Status:
Active, not recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Phase:
Phase 3
Details
Lead Sponsor:
UCB Biopharma SRL